Journal article

Decay of Fc-dependent antibody functions after mild to moderate COVID-19

Wen Shi Lee, Kevin John Selva, Samantha K Davis, Bruce D Wines, Arnold Reynaldi, Robyn Esterbauer, Hannah G Kelly, Ebene R Haycroft, Hyon-Xhi Tan, Jennifer A Juno, Adam K Wheatley, P Mark Hogarth, Deborah Cromer, Miles P Davenport, Amy W Chung, Stephen J Kent



The capacity of antibodies to engage with immune cells via the Fc region is important in preventing and controlling many infectious diseases. The evolution of such antibodies during convalescence from coronavirus disease 2019 (COVID-19) is largely unknown. We develop assays to measure Fc-dependent antibody functions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-expressing cells in serial samples from subjects primarily with mild-moderate COVID-19 up to 149 days post-infection. We find that S-specific antibodies capable of engaging Fcγ receptors decay over time, with S-specific antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis..

View full abstract


Awarded by Australian Government Medical Research Future Fund

Awarded by NHMRC

Awarded by NHMRC-EU collaborative award

Awarded by European Union

Funding Acknowledgements

We thank the cohort participants for generously providing samples. We thank Francesca Mordant and Kanta Subbarao (University of Melbourne) for performing the SARS-CoV-2 neutralization assays. We acknowledge the Melbourne Cytometry Platform for provision of flow cytometry services. The following reagent was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Spike glycoprotein receptor binding domain (RBD) from SARS-related coronavirus 2, Wuhan-Hu-1 with C-terminal histidine tag, recombinant from HEK293F cells, NR-52366. This study was supported by the Victorian Government, an Australian Government Medical Research Future Fund award GNT2002073 (S.J.K., M.P.D., and A.K.W.), the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (S.J.K.), an NHMRC program grant APP1149990 (S.J.K. and M.P.D.), NHMRC project grants GNT1162760 (A.K.W.) and GNT1145303 (P.M.H. and B.D.W.), an NHMRC-EU collaborative award APP1115828 (S.J.K. and M.P.D.), the European Union Horizon 2020 Research and Innovation Programme under grant agreement 681137 (S.J.K.), and Emergent Ventures Fast Grants (A.W.C.). J.A.J., A.W.C., and S.J.K. are supported by NHMRC fellowships. A.K.W., D.C., and M.P.D. are supported by NHMRC Investigator grants. Figures were created using BioRender.